Insmed has announced the FDA clearance of its investigational new drug (IND) application for INS1201, an innovative gene therapy for Duchenne muscular dystrophy (DMD), at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. With Phase I clinical trials set to begin in the first half of 2025, INS1201’s novel intrathecal delivery method offers the potential for safer, more effective treatments, challenging existing therapies in the DMD space, says GlobalData, a leading data and analytics company

DMD is a rare genetic disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration and weakness. The DMD treatment landscape is currently dominated by Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved gene therapy for DMD.

Elevidys delivers a micro-dystrophin gene systemically via intravenous administration, but Insmed’s INS1201 employs an innovative intrathecal delivery method to directly target the central nervous system. This approach could significantly improve safety and efficacy by reducing required doses by up to 10- to 50-fold, minimizing systemic toxicity and off-target effects.

GlobalData’s latest analysis underscores the potential of INS1201 to address key limitations of current therapies. While systemic gene therapies like Elevidys have shown promise, they face challenges related to high viral vector doses and associated toxicity. Intrathecal delivery, as demonstrated by INS1201, aims to mitigate these risks, despite challenges such as risks of spinal cord and nerve injury and infections.

INS1201 marks the first application of Insmed’s proprietary targeted adeno-associated virus (AAV) delivery platform in DMD. The program has already secured a $500,000 equity investment from CureDuchenne Ventures, highlighting strong confidence in its potential.

Insmed is also advancing RNA End-Joining (REJ) technology to expand AAV-based therapies’ capabilities, enabling delivery of larger genes for diseases such as Stargardt disease. Simultaneously, the company’s Deimmunized by Design platform is exploring redosable gene therapies to address immunogenicity barriers of existing treatments.

Asiyah Nawab, Healthcare Analyst at GlobalData, comments: “The IND clearance for INS1201 is a significant development in the DMD gene therapy space. By leveraging intrathecal delivery, Insmed’s therapy could overcome critical safety and efficacy challenges faced by systemic approaches, offering a safer and more targeted treatment option.” 

The key opinion leaders (KOLs) interviewed by GlobalData acknowledged the advancements made by Elevidys, calling it “the closest we have to a cure,” but noted its limitations, including side effects and its inability to address all DMD mutation subtypes. These gaps highlight the need for next-generation therapies like INS1201 that could broaden applicability and improve patient outcomes.

With results from Phase I clinical trials expected in Q1 2026, INS1201 represents a pivotal step forward for the DMD market.

Nawab concludes: “INS1201 has the potential to redefine the gene therapy landscape in DMD, providing patients with safer, more effective options while driving innovation in this highly challenging therapeutic area.”